SUPPLEMENTAL MATERIAL

Table S1. The baseline characteristics of the excluded and enrolled women.

	Final Enrollment				
	No	Yes	ASMD		
N	251 814	1 159 405			
Age (years)	61.98±8.65	61.19±8.29	0.0939		
Height (cm)	153.28±5.78	153.6±5.7	0.0555		
Weight (kg)	56.94±8.4	56.98±8.25	0.0049		
BMI (kg/m2)	24.21±3.17	24.13±3.14	0.0246		
WC (cm)	80.2±8.33	79.84±8.25	0.0428		
Fasting glucose	99.79±24.47	99.29±23.73	0.0205		
(mg/dL)					
SBP (mmHg)	126±16.46	125.36±16.12	0.0392		
DBP (mmHg)	77.02±10.28	76.83±10.15	0.0191		
Total cholesterol	208.02 ± 38.74	208.46±38.56	0.0115		
(mg/dL)					
HDL-C (mg/dL)	58.9±43.97	57.71±33.18	0.0306		
LDL-C (mg/dL)	125.7±39.74	126.01±38.16	0.0082		
Triglyceride (mg/dL)	134.16±82.23	132.42±78.45	0.0216		
Creatinine (mg/dL)	0.95 ± 1.2	0.88 ± 0.85	0.0693		
eGFR	81.63±29.11	82.39±28.11	0.0263		
Ever smoking (yes,%)	11424(4.68)	42939(3.7)	0.0487		
Alcohol drinking (yes,%)	30819(13.13)	146614(12.65)	0.0143		
Regular exercise (yes,%)	40240(17.2)	215488(18.59)	0.0361		
Income (Q1)	49588(19.69)	252720(21.8)	0.0519		
Obesity (yes,%)	95077(37.82)	423961(36.57)	0.0259		
Abdominal obesity	70724(28.79)	314448(27.12)	0.0372		
(yes,%)					
Diabetes mellitus	31898(12.68)	138460(11.94)	0.0225		
(yes,%)					
Hypertension (yes,%)	113239(45.03)	499928(43.12)	0.0385		
Dyslipidemia (yes,%)	78357(31.17)	362255(31.24)	0.0016		
CKD (yes,%)	30426(12.39)	128314(11.07)	0.0410		

The reported values are based on the answers provided on the questionnaire.

Among the participants who had missing data in the general health screening questionnaire (123 629, Figure 1) and in the National Cancer Screening Program questions (216 808, Figure 1), those who still had regular menstrual cycles at the time of the screening and those with a history MI or ischemic stroke were excluded. Finally, a total of 251 814 women were selected for further analyses.

N, number; ASMD, Absolute Standardized Mean Difference; BMI, body mass index; WC, Waist Circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; CKD, Chronic Kidney Disease.

Table S2. The primary outcomes in the excluded and enrolled women.

N 251814 1159405	Event 7274	Duration	IR	HR (95% CI)
	7274	2520405.0		
	7274	2520405.0		
1150405		2530485.9	2.87	1(Ref.)
1133403	31606	11684061.8	2.71	1.007(0.982,1.033)
				0.5794
251814	10743	2512375.7	4.28	1(Ref.)
1159405	45052	11613349.3	3.88	0.99(0.969,1.011)
				0.3535
251814	19584	2555723.5	7.66	1(Ref.)
1159405	77680	11795479.3	6.59	0.985(0.97,1.001)
				0.0676
	251814 1159405 251814	251814 10743 1159405 45052 251814 19584	251814 10743 2512375.7 1159405 45052 11613349.3 251814 19584 2555723.5	251814 10743 2512375.7 4.28 1159405 45052 11613349.3 3.88 251814 19584 2555723.5 7.66

Model was adjusted for age.

Incidence rate in 1,000 person-years.

N, number; IR, incidence rate; HR, hazard ratio; CI, confidence interval; MI, myocardial infarction

*Among the participants who had missing data in the general health screening questionnaire (123 629, Figure 1) and in the National Cancer Screening Program questions (216 808, Figure 1), those who still had regular menstrual cycles at the time of the screening and those with a history MI or ischemic stroke were excluded. Finally, a total of 251 814 women were selected for further analyses.

Table S3. The hazard ratio for the primary outcomes in the total participants and the respective E values.

PM	N	Event	Duration	IR	Model 1	Model 2	Model 3	Model 4	E-value	
									Point	Lower
Myocardial Infarction								2.02	1.82	
No	1139406	30721	11485997	2.67	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)		
Yes	19999	885	198064.8	4.47	1.672	1.369	1.347	1.342		
					(1.564, 1.788)	(1.28, 1.464)	(1.26, 1.441)	(1.255,1.435)		
Ischemic Stroke						1.7	1.53			
No	1139406	43866	11417053	3.84	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)		
Yes	19999	1186	196296.5	6.04	1.574	1.223	1.21	1.203		
					(1.486, 1.668)	(1.154, 1.296)	(1.142, 1.282)	(1.135, 1.275)		
All-cause mortality						1.59	1.46			
No	1139406	75479	11594348	6.51	1(Ref.)	1(Ref.)	1(Ref.)	1(Ref.)		
Yes	19999	2201	201131.2	10.94	1.679	1.184	1.165	1.158		
					(1.61, 1.752)	(1.135, 1.235)	(1.117,1.216)	(1.11,1.209)		

Incidence rate in 1,000 person-years.

Model 1: none

Model 2: age

Model 3: age, ever smoking, alcohol drinking, regular exercise, and income (Q1)

Model 4: age, ever smoking, alcohol drinking, regular exercise, income (Q1), BMI, type 2 diabetes, hypertension, dyslipidemia, $eGFR < 60 \text{ mL/min}/1.73 \text{ m}^2$, and HRT

In order to address the possibility of unmeasured confounding in Table 1, the E-values are presented in Table S3. The E-values indicate that it is less likely that the current study had the unmeasured variables that could affect the outcomes.

PM, premature menopause; N, number; IR, incidence rate; Ref, reference; Q1, lowest quartile; BMI, body mass index; HRT, hormone replacement therapy.